NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Sep 14, 2024
03:11
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
NEJM Interviews